ADC Therapeutics

ADC Therapeutics is advancing novel PBC-based antibody drug conjugates through clinical development to improve patient outcomes in multiple indications.

In June 2011, ADC Therapeutics was founded as a spinoff from Spirogen Ltd (one of our startups), which was founded in 2000 and was an early innovator in PBD-based antibody drug conjugate research.

ADC completed US$267M IPO in 2020.

Case study: Coming together for Zynlonta: how scientific expertise, funding and entrepreneurship came together for the development of an antibody-drug conjugate targeting lymphoma

Recent news